Moderna, Inc. (MRNA) saw its stock price soar 5.02% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.

The surge appears to be driven by reports that Moderna is interested in investing in production facilities in Germany, with CEO Stephane Bancel specifically mentioning the potential opportunity presented by plants that rival BioNTech has slated for closure. According to interviews with German media, Bancel stated these facilities "would be an interesting option" compared to building new ones, suggesting a strategic expansion of Moderna's manufacturing footprint in Europe.

This move is seen as a positive signal to investors about the company's growth strategy and potential cost efficiencies in expanding its production capacity, contributing to the bullish sentiment during the trading session.